PCSK9: Proprotein convertase subtilisin/kexin type 9
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Crucial player in the regulation of plasma cholesterol homeostasis.
- Drugs that act on it: 9
- With a US drug page: 3
- Type: Protein
Drugs That Act on It
Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page| Alirocumab | Approved | Subtilisin/kexin type 9 inhibitor | Inhibitor | — |
| Evolocumab | Approved | Subtilisin/kexin type 9 inhibitor | Inhibitor | — |
| Lerodalcibep | Approved | Subtilisin/kexin type 9 inhibitor | Inhibitor | — |
| Bococizumab | — | Subtilisin/kexin type 9 inhibitor | Inhibitor | — |
| Frovocimab | — | Subtilisin/kexin type 9 inhibitor | Inhibitor | — |
| Ongericimab | — | Subtilisin/kexin type 9 inhibitor | Inhibitor | — |
| Ralpancizumab | — | Subtilisin/kexin type 9 inhibitor | Inhibitor | — |
| RG-7652 | — | Subtilisin/kexin type 9 inhibitor | Inhibitor | — |
| Tafolecimab | — | Subtilisin/kexin type 9 inhibitor | Inhibitor | — |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Hypercholesterolemia, autosomal dominant, 3
- 0.82
- Cardiovascular disorder
- 0.73
- Coronary artery disorder
- 0.73
- Metabolic disease
- 0.72
- Inherited lipid metabolism disorder
- 0.72
- Hyperlipidemia
- 0.68
- Hypercholesterolemia, familial, 1
- 0.57
- Coronary atherosclerosis
- 0.57
Drugs and mechanisms are from ChEMBL CHEMBL2929 (CC BY-SA 3.0). Gene name, function (UniProt Q8NBP7, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets